CHARLEROI, Belgium -- (BUSINESS WIRE) --
Delphi Genetics SA ("Delphi") has organised a ceremony marking the placing of the first stone of its new building on the Aéropole de Charleroi.
Cédric Szpirer (CEO) and Philippe Gabant (Head of Business Development), two scientists who founded the company, have today, in the presence of Minister Jean-Claude Marcourt (Minister for the Economy, SME, and Foreign Trade), Jean-Louis Vanherweghem (President of the Université Libre de Bruxelles) and Pierre Rombaux (IGRETEC Economic & Real Estate Development Director) symbolically placed the first stone of the company's new building on the Aeropole site.
The first stone is made up of soil samples coming from the University and the research facilities that have seen the birth of Delphi's various patents. The cradle of the University of Brussels is the Solbosch Campus in Brussels. The molecular biology laboratories were in Rhode-Saint-Genèse until 1999 and since then have been moved to the Aéropole de Charleroi.
The new building will include three levels with a total area of 1,600m², will be entirely passive, and represents a budget of more than €3M. The construction enjoys the investment support of the Walloon Region and Europe.
"In addition to the symbolism, the placing of this first stone is a major step for our company and its development, and we are impatiently waiting to enter our future facilities so that we can initiate new research orientations and develop new technologies in order to meet our customers' expectations", commented Cédric Szpirer, CEO of Delphi Genetics.
About the New Facilities
On 25 June 2010, Delphi Genetics announced a €3.5 million investment on the Aéropole de Charleroi dedicated to the construction of a building and its equipment.
The building will have a total surface area of 1,600m², including 250m² of offices and meeting rooms, 650m² of research and production laboratories and 200m² of storage space. It will be able to accommodate approximately 45 people.
The building should be finished in December 2011 and fully operational by February 2012.
About Delphi Genetics SA
Founded at the end of 2001, Delphi Genetics SA develops more effective products and technologies for genetic engineering and for protein expression in bacteria by using its unique expertise in the field of the plasmid stabilisation systems. Delphi's patented Staby® technology increases recombining protein production output without use of antibiotics, which is the traditional approach. Moreover, the technology meets the recommendations of the FDA (Food and Drug Administration) and the EMA (European Medicines Agency) with regard to the elimination of antibiotic resistant genes in protein production processes for both human and veterinary use. The company has announced several licensing agreements with important pharmaceutical groups, such as Sanofi-Pasteur and GlaxoSmithKline (GSK).
For further information, please visit our website: Delphi Genetics SA
Delphi Genetics SA
Tel: +32 71 25 10 00